Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

被引：10

作者：

Eggermont, Alexander M. M. ^{[1
,2
,3
,4
]}

Kicinski, Michal ^{[5
]}

Blank, Christian U. ^{[6
]}

Mandala, Mario ^{[7
]}

V. Long, Georgina ^{[8
,9
]}

Atkinson, Victoria ^{[10
]}

Dalle, Stephane ^{[11
]}

Haydon, Andrew ^{[12
]}

Meshcheryakov, Andrey ^{[13
]}

Khattak, Adnan ^{[11
,14
,15
]}

Carlino, Matteo S. ^{[16
]}

Sandhu, Shahneen ^{[17
]}

Larkin, James ^{[18
]}

Puig, Susana ^{[19
,20
]}

Ascierto, Paolo A. ^{[21
]}

Rutkowski, Piotr ^{[22
]}

Schadendorf, Dirk ^{[23
,24
]}

Boers-Sonderen, Marye ^{[25
]}

Di Giacomo, Anna Maria ^{[26
,27
]}

van den Eertwegh, Alfonsus J. M. ^{[28
]}

Grob, Jean-Jacques ^{[29
]}

Gutzmer, Ralf ^{[30
]}

Jamal, Rahima ^{[31
]}

van Akkooi, Alexander C. J. ^{[32
,33
]}

Lorigan, Paul ^{[34
,35
]}

Grebennik, Dmitri ^{[36
]}

Kreplere, Clemens ^{[36
]}

Marreaud, Sandrine ^{[5
]}

Suciu, Stefan ^{[5
]}

Robert, Caroline ^{[37
,38
]}

机构：

[1] Tech Univ Munich, Comprehens Canc Ctr Munich, Munich, Germany

[2] Ludwig Maximilians Univ Munchen, Munich, Germany

[3] Princess Maxima Ctr, Utrecht, Netherlands

[4] Univ Med Ctr Utrecht, Utrecht, Netherlands

[5] EORTC Headquarters, Brussels, Belgium

[6] Netherlands Canc Inst Antoni Van Leeuwenhoek, Amsterdam, Netherlands

[7] Univ Perugia, Santa Maria Misericordia Hosp, Perugia, Italy

[8] Univ Sydney, Melanoma Inst Australia, Sydney, Australia

[9] Mater & Royal North Shore Hosp, Sydney, Australia

[10] Univ Queensland, Princess Alexandra Hosp, Brisbane, Australia

[11] Lyon Univ, HCL Canc Inst, Canc Res Ctr Lyon, Lyon, France

[12] Alfred Hosp, Melbourne, Australia

[13] Fed Med Biol Agcy, Lopukhin Fed Res & Clin Ctr Phys Chem Med, Moscow, Russia

[14] Univ Western Australia, Fiona Stanley Hosp, Perth, Australia

[15] Edith Cowan Univ, Perth, Australia

[16] Melanoma Inst Australia, Westmead & Blacktown Hosp, Sydney, NSW, Australia

[17] Peter MacCallum Canc Ctr, Melbourne, Australia

[18] Royal Marsden Hosp, London, England

[19] Univ Barcelona, Hosp Clin Barcelona, Barcelona, Spain

[20] CIBERER, Inst Salud Carlos III, Barcelona, Spain

[21] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[22] Mar Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[23] Univ Hosp Essen, Essen, Germany

[24] German Canc Consortium, Heidelberg, Germany

[25] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands

[26] Univ Siena, Siena, Italy

[27] Univ Hosp Siena, Ctr Immunooncol, Siena, Italy

[28] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands

[29] Aix Marseille Univ, Hop Timone, AP HM, Marseille, France

[30] Ruhr Univ Bochum, Johannes Wesling Med Ctr, Campus Minden, Minden, Germany

[31] Ctr Hosp Univ Montreal CHUM, Ctr Rech CHUM, Montreal, PQ, Canada

[32] Univ Sydney, Melanoma Inst Australia, Fac Med & Hlth, Wollstonecraft Sydney, Camperdown, NSW, Australia

[33] Royal Prince Alfred Hosp, Inst Acad Surg, Camperdown, NSW, Australia

[34] Univ Manchester, Div Canc Sci, Manchester, England

[35] Christie NHS Fdn Trust, Manchester, England

[36] Merck & Co Inc, Rahway, NJ USA

[37] Gustave Roussy Canc Campus Grand Paris, Villejuif, France

[38] Univ Paris Saclay, Villejuif, France

来源：

EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷

关键词：

Anti-PD1; Anti-PDL1; Clinical trial; Immune checkpoint inhibitors; Melanoma; Phase; 3; Immunotherapy; Pembrolizumab; Adjuvant treatment; METASTASIS-FREE SURVIVAL; DOUBLE-BLIND; COMPLETE RESECTION; IPILIMUMAB; NIVOLUMAB;

D O I：

10.1016/j.ejca.2024.114327

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the previously reported primary analyses of this phase 3 trial, 12 months of adjuvant pembrolizumab resulted in significantly longer recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) than placebo in patients with resected high risk stage III melanoma. Stability of these benefits when the median follow-up was 3.5 and 5 years was published. Here we report results with a longer follow-up. Methods: We randomized 1019 patients to receive pembrolizumab 200 mg or placebo, intravenously every 3 weeks for a total of 18 doses. RFS in the overall population and in the subgroup of patients with melanoma positive for the PD-1 ligand (PD-L1) were co-primary endpoints. DMFS in these two populations was a secondary and progression/recurrence-free survival 2 (PRFS2) an exploratory endpoint. Results: The median follow-up was 6.9 years. In the overall intention-to-treat population, RFS was longer in the pembrolizumab group than in the placebo group (HR 0.63, 95 % CI 0.53 to 0.74). RFS at 7 years was 50 % (95 % CI 46 % to 55 %) in the pembrolizumab and 36 % (95 % CI 32 % to 41 %) in the placebo group. Positive effects were present both for loco-regional recurrences and distant metastases, and across substages IIIA-IIIB-IIIC, and PD-L1 positive and PD-L1 negative as well as for BRAF mutant and BRAF wild type populations. DMFS was longer in the pembrolizumab group than in the placebo group (HR 0.64, 95 % CI 0.54 to 0.76). DMFS at 7 years was 54 % (95 % CI 50 % to 59 %) in the pembrolizumab and 42 % (95 % CI 37 % to 46 %) in the placebo group. PRFS2 was longer in the pembrolizumab group than in the placebo group (HR 0.69, 95 % CI 0.57 to 0.84). PRFS2 at 7 years was 61 % (95 % CI 57 % to 66 %) in the pembrolizumab and 53 % (95 % CI 49 % to 57 %) in the placebo group. Conclusions: The 7-year analysis of adjuvant therapy with pembrolizumab demonstrated a sustained improvement in the long-term RFS, DMFS and PRFS2 compared with placebo in patients with resected stage III melanoma.

引用

页数：10

共 34 条

[1] Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Ascierto, Paolo A.
Del Vecchio, Michele
Mandala, Mario
Gogas, Helen
Arance, Ana M.
Dalle, Stephane
Cowey, C. Lance
Schenker, Michael
Grob, Jean-Jacques
Chiarion-Sileni, Vanna
Marquez-Rodas, Ivan
Butler, Marcus O.
Maio, Michele
Middleton, Mark R.
de la Cruz-Merino, Luis
Arenberger, Petr
Atkinson, Victoria
Hill, Andrew
Fecher, Leslie A.
Millward, Michael
Khushalani, Nikhil, I
Queirolo, Paola
Lobo, Maurice
de Pril, Veerle
Loffredo, John
Larkin, James
Weber, Jeffrey
[J]. LANCET ONCOLOGY, 2020, 21 (11) : 1465 - 1477
[2] Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, Charles M.
Gershenwald, Jeffrey E.
Soong, Seng-jaw
Thompson, John F.
Atkins, Michael B.
Byrd, David R.
Buzaid, Antonio C.
Cochran, Alistair J.
Coit, Daniel G.
Ding, Shouluan
Eggermont, Alexander M.
Flaherty, Keith T.
Gimotty, Phyllis A.
Kirkwood, John M.
McMasters, Kelly M.
Mihm, Martin C., Jr.
Morton, Donald L.
Ross, Merrick I.
Sober, Arthur J.
Sondak, Vernon K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6199 - 6206
[3] Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Blank, Christian U.
Lucas, Minke W.
Scolyer, Richard A.
van de Wiel, Bart A.
Menzies, Alexander M.
Lopez-Yurda, Marta
Hoeijmakers, Lotte L.
Saw, Robyn P. M.
Lijnsvelt, Judith M.
Maher, Nigel G.
Pulleman, Saskia M.
Gonzalez, Maria
Acosta, Alejandro Torres
van Houdt, Winan J.
Lo, Serigne N.
Kuijpers, Anke M. J.
Spillane, Andrew
Klop, W. Martin C.
Pennington, Thomas E.
Zuur, Charlotte L.
Shannon, Kerwin F.
Seinstra, Beatrijs A.
Rawson, Robert V.
Haanen, John B. A. G.
Ch'ng, Sydney
Naipal, Kishan A. T.
Stretch, Jonathan
van Thienen, Johannes V.
Rtshiladze, Michael A.
Wilgenhof, Sofie
Kapoor, Rony
Meerveld-Eggink, Aafke
Grijpink-Ongering, Lindsay G.
van Akkooi, Alexander C. J.
Reijers, Irene L. M.
Gyorki, David E.
Gruenhagen, Dirk J.
Speetjens, Frank M.
Vliek, Sonja B.
Placzke, Joanna
Spain, Lavinia
Stassen, Robert C.
Amini-Adle, Mona
Lebbe, Celeste
Faries, Mark B.
Robert, Caroline
Ascierto, Paolo A.
van Rijn, Rozemarijn
van den Berkmortel, Franchette W. P. J.
Piersma, Djura
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024,
[4] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Bottomley, Andrew
Coens, Corneel
Mierzynska, Justyna
Blank, Christian U.
Mandala, Mario
Long, Georgina, V
Atkinson, Victoria G.
Dalle, Stephane
Haydon, Andrew M.
Meshcheryakov, Andrey
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Puig, Susana
Ascierto, Paolo A.
Larkin, James
Lorigan, Paul C.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Di Giacomo, Anna Maria
van den Eertwegh, Alfonsus J. M.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
van Akkooi, Alexander C. J.
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
Eggermont, Alexander M. M.
[J]. LANCET ONCOLOGY, 2021, 22 (05) : 655 - 664
[5] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Buehrer, Emanuel
Kicinski, Michal
Mandala, Mario
Pe, Madeline
Long, Georgina, V
Atkinson, Victoria
Blank, Christian U.
Haydon, Andrew
Dalle, Stephane
Khattak, Adnan
Carlino, Matteo S.
Meshcheryakov, Andrey
Sandhu, Shahneen
Puig, Susana
Schadendorf, Dirk
Jamal, Rahima
Rutkowski, Piotr
van den Eertwegh, Alfonsus J. M.
Coens, Corneel
Grebennik, Dmitri
Krepler, Clemens
Robert, Caroline
Eggermont, Alexander
[J]. LANCET ONCOLOGY, 2024, 25 (09) : 1202 - 1212
[6] COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma
Dummer, Reinhard
Flaherty, Keith T.
Robert, Caroline
Arance, Ana
de Groot, Jan Willem B.
Garbe, Claus
Gogas, Helen J.
Gutzmer, Ralf
Krajsova, Ivana
Liszkay, Gabriella
Loquai, Carmen
Mandala, Mario
Schadendorf, Dirk
Yamazaki, Naoya
di Pietro, Alessandra
Cantey-Kiser, Jean
Edwards, Michelle
Ascierto, Paolo A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36) : 4178 - +
[7] Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Dummer, Reinhard
Hauschild, Axel
Santinami, Mario
Atkinson, Victoria
Mandala, Mario
Kirkwood, John M.
Sileni, Vanna Chiarion
Larkin, James
Nyakas, Marta
Dutriaux, Caroline
Haydon, Andrew
Robert, Caroline
Mortier, Laurent
Schachter, Jacob
Lesimple, Thierry
Plummer, Ruth
Dasgupta, Kohinoor
Gasal, Eduard
Tan, Monique
Long, Georgina V.
Schadendorf, Dirk
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (12) : 1139 - 1148
[8] Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M.
Chiarion-Sileni, V.
Grob, J. -J.
Dummer, R.
Wolchok, J. D.
Schmidt, H.
Hamid, O.
Robert, C.
Ascierto, P. A.
Richards, J. M.
Lebbe, C.
Ferraresi, V.
Smylie, M.
Weber, J. S.
Maio, M.
Bastholt, L.
Mortier, L.
Thomas, L.
Tahir, S.
Hauschild, A.
Hassel, J. C.
Hodi, F. S.
Taitt, C.
de Pril, V.
de Schaetzen, G.
Suciu, S.
Testori, A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1845 - 1855
[9] Eggermont Alexander M M, 2022, NEJM Evid, V1, pEVIDoa2200214, DOI 10.1056/EVIDoa2200214
[10] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Eggermont, Alexander M. M.
Blank, Christian U.
Mandala, Mario
Long, Georgina, V
Atkinson, Victoria G.
Dalle, Stephane
Haydon, Andrew M.
Meshcheryakov, Andrey
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Giacomo, Anna Maria Di
van den Eertwegh, Alfonsus J. M.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
Lorigan, Paul C.
van Akkooi, Alexander C. J.
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
[J]. LANCET ONCOLOGY, 2021, 22 (05) : 643 - 654

← 1 2 3 4 →